Evidence map›Paper›PMID 37520571›Full record

ArticleFrontiers in immunology2023

Endogenous erythropoietin has immunoregulatory functions that limit the expression of autoimmune kidney disease in mice.

Sofia Bin, Chiara Cantarelli, Julian K Horwitz, Micaela Gentile, Manuel Alfredo Podestà, Gaetano La Manna, Peter S Heeger, Paolo Cravedi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Nobiletin: a potential erythropoietin receptor activator protects renal cells against hypoxia.Apoptosis : an international journal on programmed cell death · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Sofia BinPrecision Immunology Institute, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Chiara CantarelliDipartimento di Medicina e Chirurgia, Università di Parma, Unità Operativa (UO) Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Julian K HorwitzPrecision Immunology Institute, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Micaela GentilePrecision Immunology Institute, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Manuel Alfredo PodestàRenal Division, Department of Medicine, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Gaetano La MannaNephrology, Dialysis and Renal Transplant Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Peter S HeegerPrecision Immunology Institute, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Paolo CravediPrecision Immunology Institute, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Icahn School of Medicine at Mount Sinai · USOspedale di Parma · ITResearch Centre for Cereal and Industrial Crops · ITBrigham and Women's Hospital · US

Funding

Erythropoietin mediated immunoregulation in murine lupus nephritisR01AI132949 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CRAVEDI, PAOLO · 2018 to 2022
$2.1M
Decay Accelerating Factor and B cell ImmunityR01AI141434 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DOMINGUEZ-SOLA, DAVID, HEEGER, PETER SCOTT · 2019 to 2023
$2.1M
NIAID NIH HHS R01 AI132949NIAID NIH HHS R01 AI141434
6 · The paper itself

Abstract

Background: Administration of recombinant erythropoietin (EPO), a kidney-produced hormone with erythropoietic functions, has been shown to have multiple immunoregulatory effects in mice and humans, but whether physiological levels of EPO regulate immune function Methods: We generated mice in which we could downregulate EPO production using a doxycycline (DOX)-inducible, EPO-specific silencing RNA (shEPOrtTA Results: In B6.MRL/lpr mice, Discussion: Our data in a murine model of lupus document that endogenous EPO reduces T- and B-cell activation and autoantibody production, supporting the conclusion that EPO physiologically acts as a counterregulatory mechanism to control immune homeostasis.

Indexed as

Autoimmune DiseasesErythropoietinKidney DiseasesAnimalsHumansImmunityKidneyMiceMice, Inbred MRL lprEpo protein, mouseErythropoietinerythropoietingerminal center B cellsystemic lupus erythematosusTFHTfR

Identifiers

PMID37520571
PMCPMC10381939
OpenAlexW4384154731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.